- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05107492
Evaluation of the Pharmacokinetics, Safety and Tolerability of Single Dose of PF-06480605 in Chinese Healthy Participants
September 14, 2023 updated by: Pfizer
A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY FOLLOWING SINGLE SUBCUTANEOUS DOSE OF PF-06480605 IN CHINESE HEALTHY PARTICIPANTS
This is a Phase 1, single-center, randomized, double-blind, third-party open (ie, participant blind, investigator blind and sponsor open), placebo controlled study to investigate PK, safety, tolerability, immunogenicity, and PD of PF 06480605 following a single subcutaneous dose of PF-06480605 450 mg and 150 mg (if needed) in Chinese healthy adult participants.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Peking University Third Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Male and female participants must be 18 to 45 years of age, inclusive, at the time of signing the ICD.
- Male and female Chinese participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital sign and 12-lead ECG
- BMI of 19 to 27 kg/m2; and a total body weight >50 kg.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- History of HIV infection, hepatitis B, hepatitis C or syphilis; positive testing for HIV, hepatitis B, HCVAb or serological reaction of syphilis.
- History of allergic or anaphylactic reaction to a therapeutic drug.
- History of recent active infections within 28 days prior to the screening visit.
- Participants with a fever within 48 hours prior to dosing.
- History of TB or active or latent or inadequately treated infection.
- Recent exposure to live vaccines within 28 days of the screening visit.
- A positive pregnancy test.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 450mg and placebo arms.
|
following a single subcutaneous dose of PF-06480605 450 mg
following a single subcutaneous dose of placebo
|
Experimental: Cohort 2
12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 150mg and placebo arms.
|
following a single subcutaneous dose of placebo
following a single subcutaneous dose of PF-06480605 150 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Observed Concentration (Cmax) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Cmax is the maximum observed plasma concentration.
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Time for Cmax (Tmax) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Tmax is the time for Cmax.
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Area Under the Curve From Time 0 to End of Dosing Interval (AUC14day) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, and 336 hours post dose on Day 1
|
AUC14day is area under the curve from time 0 to end of dosing interval (Day 14, 336 hours).
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, and 336 hours post dose on Day 1
|
Area Under the Plasma Concentration Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
AUCinf is area under the plasma concentration time profile from time 0 extrapolated to infinite time.
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Terminal Half-life (t1/2) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
t1/2 is the terminal half-life (time required for the plasma concentration to decline by 50%)
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: Day 1 to Day 114
|
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events.
TEAEs were events between first dose of study drug and before the end of study (up to follow-up visits).
AEs presented below were TEAEs.
The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
|
Day 1 to Day 114
|
Number of Participants With Change From Baseline in Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria
Time Frame: From Baseline (BL) to Day 114
|
Vital signs abnormalities included: supine diastolic blood pressure (BP) increase and decrease from BL of >=20mmHg or absolute value <50mmHg; systolic BP increase and decrease from BL of >=30mmHg or absolute value <90mmHg; pulse rate <40 or >120bpm.
|
From Baseline (BL) to Day 114
|
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Data Meeting the Pre-defined Categorical Summarization Criteria
Time Frame: From BL to Day 114
|
ECG assessments included PR, QT, and QTc intervals and QRS complex.
ECG abnormalities included PR interval BL >200msec and max >=25% increase from BL, or BL <=200msec and max >=50% increase from BL, or absolute value >=300msec; QRS interval percent change from BL >=50% or absolute value >=140msec, QTcF change from BL >=30msec, or absolute value >450msec.
|
From BL to Day 114
|
Number of Participants With Clinical Laboratory Abnormalities (Without Regard to Baseline Abnormality)
Time Frame: From BL to Day 114
|
Safety laboratory assessments included clinical chemistry, hematology, urinalysis, and other tests.
Abnormality was determined at the investigator's discretion.
Laboratory test abnormalities reported by at least 1 participant are reported in this outcome measure.
|
From BL to Day 114
|
Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
AUClast is area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Apparent Volume of Distribution (Vz/F) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Vz/F is the apparent volume of distribution, defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Apparent Oral Clearance (CL/F) of PF-06480605
Time Frame: At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
CL/F is the apparent oral clearance, which is influenced by the fraction of the dose absorbed.
Clearance was estimated from population PK modeling.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
At 0 (prior to dose), 2, 6, 24, 48, 72, 96, 216, 336, 672, 1008, 1344, 2016, and 2712 hours post dose on Day 1
|
Number of Participants With Positivie Anti-drug Antibody (ADA) Against PF-06480605
Time Frame: On Days 1 (prior to dose), 15, 29, 57, 85 and 114
|
Summary of ADA incidence by visit is presented.
ADA positive was defined as titer >=60.
|
On Days 1 (prior to dose), 15, 29, 57, 85 and 114
|
Number of Participants With Neutralizing Antibody (NAb) Against PF-06480605
Time Frame: On Days 1 (prior to dose), 15, 29, 57, 85 and 114
|
Summary of NAb incidence by visit is presented.
NAb positive was defined as titer >=5.
ADA-positive participants (defined as titer >=60) were analyzed for NAb.
|
On Days 1 (prior to dose), 15, 29, 57, 85 and 114
|
Total Soluble Tumor Necrosis Factor Like Ligand 1A (sTL1A) Protein Concentration in Serum
Time Frame: On Days 1 (prior to dose), 2, 5, 15, 29, 57, 85 and 114
|
The total sTL1A protein concentration in serum is summarized by time.
|
On Days 1 (prior to dose), 2, 5, 15, 29, 57, 85 and 114
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 19, 2021
Primary Completion (Actual)
April 9, 2022
Study Completion (Actual)
April 9, 2022
Study Registration Dates
First Submitted
November 3, 2021
First Submitted That Met QC Criteria
November 3, 2021
First Posted (Actual)
November 4, 2021
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
September 14, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B7541013
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Kyungpook National University HospitalDaegu Catholic University Medical Center; Yeungnam University Hospital; DongGuk...RecruitingIdiopathic Chronic Inflammatory Bowel DiseaseKorea, Republic of
-
Assiut UniversityUnknownHepatobilliary Manifestations in Inflammatory Bowel Disease Patients
Clinical Trials on 450mg
-
Chonbuk National University HospitalCompleted
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedHypercholesterolemiaChina
-
Huabo Biopharm Co., Ltd.Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAtopic DermatitisChina
-
Chengdu Zenitar Biomedical Technology Co., LtdRecruitingRheumatoid Arthritis (RA) | Inflammatory Bowel Disease - IBD1China
-
AkesoAD Pharma (Guangdong)Completed
-
Jill M KolesarArtemiLifeRecruiting
-
University of ReadingNaurex, Inc, an affiliate of Allergan plcCompletedCognitive DeclineUnited Kingdom
-
Florida State UniversityCompletedOsteoporosis, OsteopeniaUnited States